

**Supplementary Table 3. Characteristics of kidney transplant recipients by incident post-kidney transplantation vascular dementia**

Variable	No vascular dementia (n = 8,822)	Vascular dementia (n = 19)	p-value
Age (yr)	52.5 ± 7.4	58.0 ± 6.4	0.001
40–44	1,469 (16.7)	0 (0)	
45–49	1,847 (20.9)	2 (10.5)	
50–54	2,179 (24.7)	5 (26.3)	
55–59	1,690 (19.2)	4 (21.1)	
60–64	1,086 (12.3)	4 (21.1)	
65–69	439 (5.0)	4 (21.1)	
≥70	112 (1.3)	0 (0)	
Male sex	5,347 (60.6)	13 (68.4)	0.65
Year grading (yr)			0.14
2007–2009	1,952 (22.1)	6 (31.6)	
2010–2012	3,012 (34.1)	9 (47.4)	
2013–2015	3,858 (43.7)	4 (21.1)	
Income			0.38
Medical aid	1,256 (14.2)	3 (15.8)	
Q1	1,277 (14.5)	0 (0)	
Q2	1,286 (14.6)	4 (21.1)	
Q3	1,815 (20.6)	3 (15.8)	
Q4	3,188 (36.1)	9 (47.4)	
Charlson comorbidity index			0.09
0	64 (0.7)	0 (0)	
1–2	2,622 (29.7)	2 (10.5)	
3–4	2,562 (29.0)	4 (21.1)	
≥5	3,574 (40.5)	13 (68.4)	
Diabetes mellitus	3,773 (42.8)	14 (73.7)	0.01
Hypertension	8,204 (93.0)	19 (100)	0.46
Dyslipidemia	4,954 (56.2)	12 (63.2)	0.70
Cardiovascular disease	2,144 (24.3)	5 (26.3)	>0.99
Dialysis modality			0.75
Preemptive	2,835 (32.1)	6 (31.6)	
Hemodialysis	3,869 (43.9)	9 (47.4)	
Peritoneal dialysis	1,609 (18.2)	4 (21.1)	
Mixed	509 (5.8)	0 (0)	
Dialysis vintage period	3.0 ± 3.4	2.1 ± 2.6	0.26
<3 mo	3,209 (36.4)	6 (31.6)	
3 mo–1 yr	755 (8.6)	3 (15.8)	
1–2 yr	666 (7.5)	3 (15.8)	
2–3 yr	572 (6.5)	2 (10.5)	
3–4 yr	570 (6.5)	0 (0)	
4–5 yr	556 (6.3)	1 (5.3)	
>5 yr	2,494 (28.3)	4 (21.1)	
Immunosuppressive treatment			
Desensitization	1,469 (16.7)	3 (15.8)	>0.99
Induction			0.53
No use	370 (4.2)	0 (0)	
ATG	823 (9.3)	1 (5.3)	
Basiliximab	7,629 (86.5)	18 (94.7)	
Maintenance CNI			0.76
No use	242 (2.7)	0 (0)	
Tacrolimus	7,250 (82.2)	16 (84.2)	
Cyclosporine	1,330 (15.1)	3 (15.8)	

Data are expressed as mean ± standard deviation or number (%).  
 ATG, antithymocyte globulin; CNI, calcineurin inhibitor; Q, quartile.